All Companies

Abide Tx
Fo­cused on de­vel­op­ing first-in-class serine hy­dro­lase-tar­get­ed ther­a­peu­tics that har­ness the po­ten­tial of the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal di­s­or­ders and pain di­s­or­ders with limit­ed... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$181 MM MCap
De­vel­op­ing ther­a­pies for use in med­i­cal­ly su­per­vised sett­ings. Re­cent­ly ap­proved DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) is in­di­cat­ed for the ma­n­age­ment of acute pain se­vere enough to re­quire an... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc.
Cre­at­ing and com­mer­cial­iz­ing a new gen­er­a­tion of medicines in­tend­ed to lessen the bur­den of chron­ic neu­ro­log­ic dis­eas­es on pa­tients, care­givers and so­ci­e­ty us­ing its deep un­der­s­tand­ing of... [more in­for­ma­tion]
Af­fi­body is a clin­i­cal stage Swedish biotech com­pany fo­cused on de­vel­op­ing next gen­er­a­tion bio­phar­ma­ceu­ti­cals based on its unique pro­pri­e­tary tech­nol­o­gy plat­forms: Af­fi­body® molecules and Al­bu­mod™. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$266 MM MCap
Dis­cov­ers and de­vel­ops high­ly tar­get­ed can­cer im­munother­a­pies en­gi­neered from Af­fimed’s pro­pri­e­tary, mo­d­u­lar ROCK™ (Redi­rect­ed Op­ti­mized Cell Killing) plat­form that en­ables the gen­er­a­tion of... [more in­for­ma­tion]
Amarin Corporation [AMRN] US$5,720 MM MCap
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in... [more in­for­ma­tion]
Aptorum Group
Ap­to­rum Group is a Hong Kong-based life sci­ence and bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to ac­quir­ing, de­vel­op­ing and com­mer­cial­iz­ing nov­el bio­phar­ma­ceu­ti­cal prod­ucts and in­no­va­tions around the world. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$628 MM MCap
As­sem­b­ly Bio­s­ciences, Inc. is a clin­i­cal-stage public biotech­nol­o­gy com­pany de­vel­op­ing two in­no­va­tive plat­form pro­grams: an HBV pro­gram ad­vanc­ing a new class of oral ther­a­peu­tics for the treat­ment of... [more in­for­ma­tion]
AxoGen [AXGN] US$1,236 MM MCap
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$186 MM MCap
De­vel­op­ing cell ther­a­pies with molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­abling phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram is a Ph2 for... [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,691 MM MCap
Ber­Gen­Bio ASA is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing a pipe­line of first-in-class AXL ki­nase in­hibi­tors as a po­ten­tial corn­er­s­tone of com­bi­na­tion can­cer ther­a­py. The... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$1,408 MM MCap
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX [BPMX] US$33 MM MCap
Der­ma­tol­o­gy-fo­cused, de­vel­op­ing BPX-01 for top­i­cal mino­cy­c­line acne and rosacea treat­ment, based on its nov­el hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. Re­port­ed Ph 2b da­ta with BPX-01 in acne. Phase... [more in­for­ma­tion]
BioTime, Inc [BTX] US$237 MM MCap
Bi­o­Time, Inc. (NYSE Amer­i­can: BTX) is a clin­i­cal-stage biotech­nol­o­gy com­pany de­vel­op­ing cell-based ther­a­pies for the treat­ment of de­gen­er­a­tive dis­eas­es. Their lead cell re­place­ment prod­uct can­di­date... [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$65 MM MCap
De­vel­op­ing in­no­va­tive, au­tol­o­gous stem cell ther­a­pies for high­ly de­bil­i­tat­ing neu­rode­gen­er­a­tive dis­eas­es lev­er­ag­ing the Com­pany’s NurOwn® cell ther­a­py plat­form. Brain­S­torm’s lead drug can­di­date... [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr3,266 MM MCap
Com­mitt­ed to de­vel­op­ing and com­mer­cial­iz­ing in­no­va­tive and long-act­ing medicines for the treat­ment of se­vere and chron­ic con­di­tions, in­clud­ing opi­oid de­pen­dence, pain, can­cer and en­docrine di­s­or­ders. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$384 MM MCap
A bio­phar­ma­ceu­ti­cal com­pany fo­cused on the ac­qui­si­tion, de­vel­op­ment, and com­mer­cial­iza­tion of in­no­va­tive ther­a­peu­tics ad­dress­ing CAN­CER and other un­met med­i­cal needs for the glob­al mar­ket, with a... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$317 MM MCap
De­vel­op­ing Fir­dapse for the treat­ment of or­phan dis­ease in­di­ca­tion, Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) - 2 pos­i­tive Ph 3 trials com­plet­ed, NDA ac­cept­ed with pri­or­i­ty re­view. PD­U­FA date of Nov... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$98 MM MCap
CTI Bio­pha­ma’s lead can­di­date pa­cri­tinib, an oral ki­nase in­hibi­tor with spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in ph2 for the treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts – CHMP opinion in... [more in­for­ma­tion]
CureVac AG
Found­ing com­pany of the mR­NA space (pri­vate, Ger­man, with the last round val­u­a­tion over $1bn). MOA: Na­t­u­ral­ly se­quenced, op­ti­mized mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 trial (mul­ti­ple on­col­o­gy in­di­ca­tions)... [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$145 MM MCap
De­vel­op re­search tools, di­ag­nos­tics and ther­a­peu­tics and pro­vides ref­er­ence lab­o­ra­to­ry ser­vices to the med­i­cal com­mu­ni­ty. Ac­tiv­i­ties in­clude R&D, man­u­fac­tur­ing and mar­ket­ing of biomed­i­cal re­search... [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$19 MM MCap
Clin­i­cal stage com­pany fo­cused on the de­vel­op­ment of small molecule drugs for the treat­ment of cas­tra­tion-re­sis­tant pros­tate can­cer. The com­pa­nies lead can­di­date, EPI-506, is ex­pect­ed to en­ter the... [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$91 MM MCap
Lead prod­uct Am­pho­ra, a non-hor­mo­n­al, on-de­mand, wo­m­an-con­trolled con­tra­cep­tive vag­i­nal gel, is cur­rent­ly com­plet­ing a con­fir­ma­to­ry Phase 3 trial in 1400 wo­m­en in the US. The Com­pany ex­pects to re­port... [more in­for­ma­tion]
Forbius (Formation Biologics)
Clin­i­cal-stage com­pany uti­l­iz­ing com­ple­men­tary pro­tein en­gi­neer­ing plat­forms to de­sign to high­ly ac­tive and se­lec­tive in­hibi­tors of TGF-Be­ta and EGFR path­ways for use on­col­o­gy and fi­brot­ic dis­eas­es. [more in­for­ma­tion]
Forward Pharma A/S [FWP] US$60 MM MCap
For­ward Phar­ma A/S is a Dan­ish bio­phar­ma­ceu­ti­cal com­pany that com­menced de­vel­op­ment in 2005 of FP187®, a pro­pri­e­tary for­mu­la­tion of DMF for the treat­ment of in­flam­ma­to­ry and neu­ro­log­i­cal in­di­ca­tions. [more in­for­ma­tion]
Genfit SA [GNFTF] US$717 MM MCap
Lead pro­gram Ela­fi­branor is a PPAR al­pha/del­ta ag­on­ist in Ph 3 for NASH and Ph 2 for PBC. Ful­ly en­rolled in Phase 3 RE­SOLVE-IT trial for NASH with ex­pect­ed by YE 2019. Phase 2 PBC da­ta ex­pect­ed by YE... [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €58 MM MCap
In­no­va­tive gene ther­a­pies for reti­nal and CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Lead prod­uct, GS010, is in Ph 3 for the treat­ment of Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON). RE­V­ERSE... [more in­for­ma­tion]
Hae­maLogiX is a pri­vate im­muno-on­col­o­gy com­pany with an ini­tial fo­cus on nov­el tar­gets in Mul­ti­ple Myelo­ma and an R&D col­lab­o­ra­tion with Take­da. Their Mul­ti­ple Myelo­ma (Kap­paMab) is in Ph IIb with... [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$4,013 MM MCap
Chi-Med's pipe­line has eight nov­el late stage on­col­o­gy can­di­dates with six Phase 3 trials and 20+ Phase 1b/2 trials cur­rent­ly un­der­way that are fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$203 MM MCap
Lead can­di­date IMO-2125 is used in com­bi­na­tion with Ip­ilu­mumab in PD1 re­frac­to­ry me­lano­ma pa­tients. Ph 3 trial ini­ti­a­tion is planned for 1Q18; Idera cont­in­ues to en­roll more pa­tients in­to their Ph 2... [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent opi­oid prod­uct)... [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$1,180 MM MCap
Former­ly Li­on Biotech. De­vel­op­ing can­cer im­munother­a­pies based on tu­mor in­fil­trat­ing lym­pho­cytes (TIL). Lead prod­uct, LN-144 is an au­tol­o­gous cell ther­a­py that has de­mon­s­trat­ed dist­inc­tive ef­fi­ca­cy in... [more in­for­ma­tion]
Kadmon Holdings, LLC [KDMN] US$296 MM MCap
De­vel­op­ing small molecules and bi­o­log­ics within au­toim­mune and fi­brot­ic dis­eas­es, on­col­o­gy and ge­net­ic dis­eas­es. Port­fo­lio of sm molecule ROCK in­hibi­tors in PC and clin­i­cal de­vt treat­ing au­toim­mune,... [more in­for­ma­tion]
Loxo Oncology, Inc. [LOXO] US$4,792 MM MCap
De­vel­ops tar­get­ed drugs for the treat­ment of can­cer in ge­net­i­cal­ly defined pa­tient pop­u­la­tions. Lead pro­gram: pur­pose built pan TRK in­hibi­tor in a Ph 2 solid tu­mor study with FDA break­through... [more in­for­ma­tion]
Medigene AG [MDG1:DB] €237 MM MCap
Lead­er in T Cell im­munol­o­gy. TCR tar­get­ing PRAME (AML, MDS, MM) en­tered clin­ic March 2018. CTA sub­mitt­ed for TCR tar­get­ing MAGE-A1 (MM, liv­er, and lung can­cer); sev­er­al add'l undis­closed tar­gets &... [more in­for­ma­tion]
Medivir AB [MVIR.B-SE]
Broad pipe­line of clin­i­cal stage as­sets in­clud­ing remeti­no­s­tat, a Ph 3 ready top­i­cal HDAC in­hibi­tor for the treat­ment of ear­ly-stage cu­ta­neous T-cell lym­pho­ma (CT­CL). Re­cent­ly an­nounced to­p­line da­ta... [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$327 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]
Modus Therapeutics AB
Mo­dus Ther­a­peu­tics is a Swedish-based biotech­nol­o­gy com­pany ded­i­cat­ed to de­vel­op­ing ther­a­pies that im­prove blood flow and oxy­gen tran­s­port. The com­pany’s lead pro­ject, se­vu­parin, is cur­rent­ly in an... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$114 MM MCap
Antibi­ot­ic com­pany (PD­U­FA date of Fe­bruary 13, 2019) fo­cused on gram-pos­i­tive in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. To­p­line re­sults with Iclaprim in pa­tients with acute bac­te­rial skin... [more in­for­ma­tion]
A clin­i­cal-stage CNS com­pany de­vel­op­ing the first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 is in Phase 2b/3 de­vel­op­ment (SPA and Fast Track... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing a unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Tech­nol­o­gy us­es syn­thet­ic nano­par­ti­cles de­c­o­rat­ed with a com­bi­na­tion of mul­ti­ple tu­mor rel­e­vant anti­gens and... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr6,787 MM MCap
De­vel­op­ing Melflufen (Yga­lo), an alky­lat­ing pep­tide in the nov­el class of Pep­ti­dase En­hanced Com­pounds (PEnCs), tar­get­ing the MM trans­for­ma­tion pro­cess which se­lec­tive­ly tar­gets MM. Yga­lo has a unique... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
Oventus Medical [OVN-ASX]
Oven­tus is an Aus­tralian-based, med­i­cal de­vice com­pany estab­lished in 2012 to meet the un­met needs of Ob­struc­tive Sleep Ap­ne­ics, nasal ob­struc­ters and non-com­pliant CPAP users. In 2013, Oven­tus worked... [more in­for­ma­tion]
Fo­cused on anes­th­e­sia around game chang­ing as­set Remi­ma­zo­lam, a short-act­ing anes­thet­ic. Remi­ma­zo­lam com­plet­ed a pos­i­tive Ph 3 study in pro­ce­du­ral se­da­tion in the US. Pos­i­tive safe­ty da­ta in ASA... [more in­for­ma­tion]
PharmaMar SA [PHM:MA]
1H 2017 to­tal rev­enues of &eu­ro;96.9M. Yon­delis for soft tis­sue sar­co­ma and ovarian can­cer is com­mer­cial­ized with a di­rect sales-force in Eu­rope and part­n­er­ship in US with Janssen. Zep­syre cur­rent­ly in... [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €498 MM MCap
RU­CON­EST (rhC1INH) mar­ket­ed to treat acute Hered­i­tary An­gioede­ma (HAE) at­tacks with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. Sub­mitt­ed sBLA to FDA for pro­phy­laxis of HAE (re­cent... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc.
Clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of ther­a­pies for the treat­ment of or­phan dis­eas­es, with an ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. The com­pany’s lead... [more in­for­ma­tion]
Phosphagenics [PPGNY] US$15 MM MCap
The com­pany's pro­pri­e­tary sol­u­bil­i­sa­tion / drug de­liv­ery tech­nol­o­gy TPM (Tar­get­ed Pen­e­tra­tion Ma­trix) is com­bin­ing mul­ti­ple forms of Vi­ta­min E. The plat­form en­hances the us­a­bil­i­ty char­ac­teris­tics for... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$188 MM MCap
Plat­form tech­nol­o­gy com­pany de­vel­op­ing An­ti­calins (en­gi­neered lipo­calin pro­teins) for on­col­o­gy and re­s­pi­ra­to­ry dis­eas­es. 2H18 Phase I da­ta for: 1) ful­ly-pro­pri­e­tary IO pro­gram PRS-343 for HER2+ solid... [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Pliant Ther­a­peu­tics is fo­cused on dis­cov­er­ing, de­vel­op­ing and com­mer­cial­iz­ing break­through treat­ments for fi­brot­ic dis­eas­es. By har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-&be­ta;... [more in­for­ma­tion]
Poxel SA [POXEL:PA] €139 MM MCap
De­vel­op­ing safer and more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (a mi­to­chon­dria-based MOA) for Type 2 di­a­betes be­gan Ph 3 trial in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$212 MM MCap
Pro­ta­g­on­ist uti­l­izes a pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op first-in-class oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways that are cur­rent­ly tar­get­ed by... [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$66 MM MCap
Fo­cused on re­com­bi­nant ther­a­peu­tic pro­teins pro­duced us­ing Pro­CellEx®, a plant cell-based pro­tein ex­pres­sion sys­tem. Lead as­set, PRX-102, a mod­i­fied ver­sion of the re­com­bi­nant hu­man al­pha-GAL-A... [more in­for­ma­tion]
PsiOxus Therapeutics
PsiOxus is a UK based on­co­lyt­ic gene ther­a­py com­pany ded­i­cat­ed to dis­cov­er­ing and de­vel­op­ing in­no­va­tive im­muno-on­col­o­gy treat­ments for solid tu­mors us­ing a pro­pri­e­tary in­tra­ve­nous­ly ad­min­is­tered... [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$215 MM MCap
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
ReNeuron Group plc [RENE:LN] £19 MM MCap
Clin­i­cal-stage, UK-based cell ther­a­py com­pany with al­lo­gene­ic, off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 trial de­sign ap­proved by FDA, ini­ti­a­tion mid 2018); re­tini­tis pig­men­tosa (Ph1/2... [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] US$477 MM MCap
Rigel Phar­ma­ceu­ti­cals is ded­i­cat­ed to dis­cov­er­ing, de­vel­op­ing and pro­vid­ing nov­el small molecule drugs for im­mune and he­ma­to­log­ic di­s­or­ders, can­cer and rare dis­eas­es. The com­pany's first FDA ap­proved... [more in­for­ma­tion]
Savara Inc. [SVRA] US$330 MM MCap
Sa­vara is an or­phan lung dis­ease com­pany. Sa­vara's pipe­line com­pris­es Mol­gradex, an in­haled gran­u­lo­cyte-macrophage colony-sti­m­u­lat­ing fac­tor (GM-CSF) in Phase 3 de­vel­op­ment for au­toim­mune pul­mo­nary... [more in­for­ma­tion]
Selvita S.A [WSE: SLV]
Broad on­col­o­gy tar­get­ed ther­a­peu­tics pipe­line in­cludes ki­nase in­hibi­tor and syn­thet­ic lethal­i­ty pro­grams. Lead pro­grams in­clude SEL24, a first in class PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML... [more in­for­ma­tion]
Sernova [SEOVF] US$24 MM MCap
Ser­no­va Corp. is a clin­i­cal-stage re­gen­er­a­tive medicine com­pany com­mer­cial­iz­ing prod­ucts which ben­e­fit pa­tients with chron­ic metabolic, neu­ro­log­i­cal and he­ma­to­log­i­cal dis­eas­es with first ther­a­peu­tic... [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$362 MM MCap
De­vel­op­ing three clin­i­cal stage on­col­o­gy prod­uct can­di­dates. EL­ZON­RIS is a tar­get­ed ther­a­py di­rect­ed to the in­ter­leukin-3 re­cep­tor (CD123) pre­sent on a range of ma­lig­nan­cies that suc­cess­ful­ly... [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €661 MM MCap
Mar­ket lead­er in au­to­ma­tion sys­tems and soft­ware for the di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS... [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$241 MM MCap
Glob­al com­mer­cial-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on rare dis­eas­es with sig­ni­f­i­cant un­met needs. Strong­bridge's rare en­docrine franchise in­cludes RE­COR­LEV™, a cor­ti­sol syn­th­e­sis in­hibi­tor in... [more in­for­ma­tion]
Syneos Health [SYNH] US$5,161 MM MCap
On­ly ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions or­gani­za­tion in­clud­ing a Con­tract Re­search Or­gani­za­tion (CRO) and Con­tract Com­mer­cial Or­gani­za­tion (CCO). Cre­at­ed through the merg­er of two in­dus­try... [more in­for­ma­tion]
Taiwan Liposome Company (TLC) [4152.TW]
Fo­cused on R&D and com­mer­cial­iza­tion of in­no­va­tive pain ma­n­age­ment, oph­thal­mol­o­gy, and on­col­o­gy prod­ucts based on its pro­pri­e­tary lipid-based de­liv­ery plat­forms. Pro­grams in Phase 2 trials in­clude... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr407 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer us­ing cell ther­a­py and com­bi­na­tion ap­proach­es. Tes­sa’s Virus-Spe­cif­ic T cell (VST) plat­form redi­rects body’s po­tent... [more in­for­ma­tion]
Valbiotis [AVAL-FR]
De­vel­op­ing pro­pri­e­tary plant-de­rived prod­ucts to pre­vent metabolic dis­eas­es. Ini­tial pipe­line in­cludes 5+ prod­ucts tar­get­ing pre­di­a­betes/T2D, NAFL/NASH, dys­lipi­daemia, and obe­si­ty. Lead pro­gram... [more in­for­ma­tion]
Vericel Corporation [VCEL] US$736 MM MCap
Avanced cell ther­a­py com­pany, mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of . Epi­cel mar­ket of over $2b. Re­cord 3Q18 rev­enues of $22.5 M rep­re­sents 58% y/o/y in­crease. FY... [more in­for­ma­tion]
Verseon [VSN-LON]
De­vel­op­ing com­pounds us­ing its pro­pri­e­tary in-house drug dis­cov­ery plat­form, built with over 10+ years of R&D. Po­ten­tial­ly the first sys­te­m­at­ic, com­pu­ta­tio­n­al­ly-driv­en so­lu­tion to achieve the... [more in­for­ma­tion]
Veru Healthcare [VERU] US$75 MM MCap
De­vel­op­ing nov­el medicines for pros­tate can­cer and spe­cial­ty phar­ma­ceu­ti­cals in urol­o­gy. Zu­clomiphene is be­ing eval­u­at­ed in a Phase 2 trial to treat hot flash­es caused by hor­mone treat­ment for... [more in­for­ma­tion]
Viela Bio
Pi­oneer­ing and ad­vanc­ing treat­ments for se­vere in­flam­ma­tion and au­toim­mune dis­eas­es by se­lec­tive­ly tar­get­ing shared crit­i­cal path­ways driv­ing dis­ease patho­ge­n­e­sis. Lead pro­gram, Ine­bi­l­izumab, is a... [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$75 MM MCap
Da­ta-in hand from two Ph. 2 Di­a­betes (T2) trials: 1. Glu­cok­i­nase Ac­ti­va­tor (TT­P399); 2. Oral GLP-1r (TT­P273). Eval­u­at­ing TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in... [more in­for­ma­tion]
Yisheng Biopharma
De­vel­op­ing in­no­va­tive bio­ther­a­peu­tics for can­cers and in­fec­tious dis­ease us­ing nov­el PI­KA® im­muno­mo­d­u­lat­ing tech­nol­o­gy. PI­KA® tech­nol­o­gy is able to in­flu­ence both in­nate and adap­tive im­mune... [more in­for­ma­tion]
ZIOPHARM Oncology Inc [ZIOP] US$456 MM MCap
The com­pany is fo­cused on the de­vel­op­ment of two plat­form tech­nolo­gies de­signed to de­liv­er safe, ef­fec­tive and scal­able cell- and vi­ral-based ther­a­pies for the treat­ment of mul­ti­ple can­cer types: (1)... [more in­for­ma­tion]